JP2015524816A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015524816A5 JP2015524816A5 JP2015524798A JP2015524798A JP2015524816A5 JP 2015524816 A5 JP2015524816 A5 JP 2015524816A5 JP 2015524798 A JP2015524798 A JP 2015524798A JP 2015524798 A JP2015524798 A JP 2015524798A JP 2015524816 A5 JP2015524816 A5 JP 2015524816A5
- Authority
- JP
- Japan
- Prior art keywords
- tfr1
- antibody
- antagonist
- isolated
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000007238 Transferrin Receptors Human genes 0.000 claims 11
- 108010033576 Transferrin Receptors Proteins 0.000 claims 11
- 239000005557 antagonist Substances 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 208000002903 Thalassemia Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 102000004338 Transferrin Human genes 0.000 claims 1
- 108090000901 Transferrin Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305955 | 2012-08-02 | ||
| EP12305955.2 | 2012-08-02 | ||
| PCT/EP2013/066253 WO2014020140A1 (en) | 2012-08-02 | 2013-08-02 | Use of transferrin receptor antagonist for the treatment of thalassemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015524816A JP2015524816A (ja) | 2015-08-27 |
| JP2015524816A5 true JP2015524816A5 (enExample) | 2016-09-23 |
Family
ID=48979730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015524798A Withdrawn JP2015524816A (ja) | 2012-08-02 | 2013-08-02 | サラセミアを処置するためのトランスフェリンレセプターアンタゴニストの使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20150197574A1 (enExample) |
| EP (1) | EP2880059A1 (enExample) |
| JP (1) | JP2015524816A (enExample) |
| WO (1) | WO2014020140A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2977785C (en) * | 2015-01-21 | 2025-05-06 | The Children's Hospital Of Philadelphia | Viral Vectors for the Prophylaxis and Therapy of Hemoglobinopathies |
| TWI726879B (zh) | 2015-05-04 | 2021-05-11 | 美商Ｃｙｔｏｍｘ生物製藥公司 | 抗ｃｄ７１抗體類、可活化之抗ｃｄ７１抗體類及使用彼等之方法 |
| JP6858185B2 (ja) * | 2015-07-22 | 2021-04-14 | イナサリス | 増殖性および炎症性疾患の処置における抗ＴｆＲ抗体およびその使用 |
| JP2020511130A (ja) | 2017-03-09 | 2020-04-16 | サイトメックス セラピューティクス インコーポレイテッド | Ｃｄ１４７抗体、活性化可能ｃｄ１４７抗体、ならびにその作製および使用の方法 |
| WO2018185341A1 (en) | 2017-04-07 | 2018-10-11 | Ospedale San Raffaele S.R.L. | Regulator of bmp-smad signaling and uses thereof |
| EP3762420A1 (en) | 2018-03-09 | 2021-01-13 | CytomX Therapeutics, Inc. | Activatable cd147 antibodies and methods of making and use thereof |
| JP7410051B2 (ja) * | 2018-11-20 | 2024-01-09 | 株式会社ペルセウスプロテオミクス | 細胞内への鉄の取り込み阻害剤 |
| WO2021061867A1 (en) | 2019-09-23 | 2021-04-01 | Cytomx Therapeutics, Inc. | Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof |
| US20230159652A1 (en) * | 2020-03-23 | 2023-05-25 | The Regents Of The University Of California | Transferrin receptor 1 targeting for carcinogenesis prevention |
| US20240100049A1 (en) * | 2021-01-28 | 2024-03-28 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Reactivation of embryonic and fetal hemoglobin |
| US11939391B2 (en) * | 2021-12-06 | 2024-03-26 | MedAbome, Inc. | Anti-TfR1 antibody MAb11-22.1 conjugates for cancer treatment |
| AU2024299328A1 (en) * | 2023-07-21 | 2026-01-22 | Marrow Therapeutics, Inc. | Hematopoietic cell targeting conjugates and related methods |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| AU3075801A (en) * | 1999-12-23 | 2001-07-03 | Human Genome Sciences, Inc. | Transferrin polynucleotides, polypeptides, and antibodies |
| US8129504B2 (en) * | 2001-08-30 | 2012-03-06 | Biorexis Technology, Inc. | Oral delivery of modified transferrin fusion proteins |
| ATE537189T1 (de) * | 2004-04-30 | 2011-12-15 | Inst Nat Sante Rech Med | Anti-tfr-antikörper |
-
2013
- 2013-08-02 WO PCT/EP2013/066253 patent/WO2014020140A1/en not_active Ceased
- 2013-08-02 EP EP13748004.2A patent/EP2880059A1/en not_active Withdrawn
- 2013-08-02 US US14/418,457 patent/US20150197574A1/en not_active Abandoned
- 2013-08-02 JP JP2015524798A patent/JP2015524816A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015524816A5 (enExample) | ||
| JP2011157378A5 (enExample) | ||
| CL2015000578A1 (es) | Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer. | |
| JP2012121878A5 (enExample) | ||
| HRP20241145T1 (hr) | Biciklički aza spojevi kao agonisti muskarinskih receptora | |
| JP2013519675A5 (enExample) | ||
| WO2020115555A3 (en) | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia | |
| CL2013003051A1 (es) | Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio | |
| GEP20186839B (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| HRP20190008T4 (hr) | Prevencija i liječenje sinukleinopatske i amiloidogene bolesti | |
| JP2015530399A5 (enExample) | ||
| JP2012518624A5 (enExample) | ||
| UY32599A (es) | Formulación oral sólida de abt-263 | |
| JP2012193216A5 (enExample) | ||
| PH12016502103A1 (en) | Novel disubstituted 1,2, 4-triazine compound | |
| CL2013003333A1 (es) | Compuestos derivados de pregnenolona, antagonistas de receptor cb1; composicion farmaceutica: y su uso para el tratamiento de trastornos de la vejiga y gastrointestinales, enfermedades inflamatorias, cardiovasculares, entre otras. | |
| WO2015116856A3 (en) | Farnesoid x receptor antagonists | |
| CN103717571B8 (zh) | 9‑氨基甲基取代的四环素类化合物 | |
| JP2016502515A5 (enExample) | ||
| GEP201606526B (en) | 5-ht3 receptor antagonists | |
| HK1244429A1 (zh) | 特别用於治疗注意力缺陷障碍的方法和组合物 | |
| WO2015023504A8 (en) | Methods for reducing exacerbation rates of asthma using benralizumab | |
| JP2015526455A5 (enExample) | ||
| HRP20220683T1 (hr) | Liječenje parkinsonove bolesti | |
| IL230487B (en) | 6-(n-(7-chloro-1-hydroxy-3,1-dihydrobenzo[c][1,2]oxaborole-5-yl)methylsulfonamido)-5-cyclopropyl-2-(4-fluorophenyl)-n- Methylbenzofuran-3-carboxamide, their salts and pharmaceutical preparations containing them |